首页 > 最新文献

Breast disease最新文献

英文 中文
The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study). Fas/FasL通路阻断对乳腺癌肿瘤微环境中细胞凋亡和干细胞的影响(临床前研究)。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220077
Seham Abou Shousha, Suzan Baheeg, Hossam Ghoneim, Malak Zoheir, Mahmoud Hemida, Yasmine Shahine

Evasion of the immune system is the tumor's key strategy for its maintenance and progression. Thus, targeting the tumor microenvironment (TME) is considered one of the most promising approaches for fighting cancer, where immune cells within the TME play a vital role in immune surveillance and cancer elimination.FasL is one of the most important death ligands expressed by tumor-infiltrating lymphocytes (TILs) and plays a vital role in eliminating Fas-expressing cancer cells via Fas/FasL pathway-induced apoptosis. However, tumor cells can express elevated levels of FasL inducing apoptosis to TILs. Fas/FasL expression is linked to the maintenance of cancer stem cells (CSCs) within the TME, contributing to tumor aggressiveness, metastasis, recurrence, and chemoresistance.This study is considered the first study designed to block the overexpressed FasL on the tumor cells within TME mimicking tissue culture system using rFas molecules and supplementing the Fas enriched tissue culture system with blocked Fas - peripheral blood mononuclear cells PBMCs (using anti-Fas mAb) to protect them from tumor counterattack and augment their ability to induce tumor cell apoptosis and stemness inhibition.A significantly increased level of apoptosis and decreased expression of CD 44 (CSCs marker) was observed within the east tumor tissue culture system enriched with Fas molecules and anti-Fas treated PBMCs and the one enriched with Fas molecules only compared to the breast tumor tissues cultured alone (p < 0.001). Accordingly, we can consider the current study as a promising proposed immunotherapeutic strategy for breast cancer.

逃避免疫系统是肿瘤维持和发展的关键策略。因此,靶向肿瘤微环境(TME)被认为是最有前途的抗癌方法之一,其中TME内的免疫细胞在免疫监视和癌症消除中起着至关重要的作用。FasL是肿瘤浸润淋巴细胞(tumor-浸润淋巴细胞,til)表达的最重要的死亡配体之一,通过Fas/FasL通路诱导凋亡,在消灭表达Fas的癌细胞中起着至关重要的作用。然而,肿瘤细胞可以表达高水平的FasL诱导TILs凋亡。Fas/FasL表达与TME内肿瘤干细胞(CSCs)的维持有关,有助于肿瘤的侵袭性、转移、复发和化疗耐药。本研究被认为是第一个在TME模拟组织培养系统中,利用rFas分子阻断肿瘤细胞上过表达的FasL,并在富含Fas的组织培养系统中补充被阻断的Fas -外周血单核细胞PBMCs(使用anti-Fas mAb),以保护它们免受肿瘤的攻击,并增强其诱导肿瘤细胞凋亡和干细胞抑制的能力的研究。与单独培养的乳腺肿瘤组织相比,在富含Fas分子和抗Fas处理的PBMCs以及仅富含Fas分子的PBMCs中,细胞凋亡水平显著增加,cd44 (CSCs标志物)的表达显著降低(p
{"title":"The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study).","authors":"Seham Abou Shousha,&nbsp;Suzan Baheeg,&nbsp;Hossam Ghoneim,&nbsp;Malak Zoheir,&nbsp;Mahmoud Hemida,&nbsp;Yasmine Shahine","doi":"10.3233/BD-220077","DOIUrl":"https://doi.org/10.3233/BD-220077","url":null,"abstract":"<p><p>Evasion of the immune system is the tumor's key strategy for its maintenance and progression. Thus, targeting the tumor microenvironment (TME) is considered one of the most promising approaches for fighting cancer, where immune cells within the TME play a vital role in immune surveillance and cancer elimination.FasL is one of the most important death ligands expressed by tumor-infiltrating lymphocytes (TILs) and plays a vital role in eliminating Fas-expressing cancer cells via Fas/FasL pathway-induced apoptosis. However, tumor cells can express elevated levels of FasL inducing apoptosis to TILs. Fas/FasL expression is linked to the maintenance of cancer stem cells (CSCs) within the TME, contributing to tumor aggressiveness, metastasis, recurrence, and chemoresistance.This study is considered the first study designed to block the overexpressed FasL on the tumor cells within TME mimicking tissue culture system using rFas molecules and supplementing the Fas enriched tissue culture system with blocked Fas - peripheral blood mononuclear cells PBMCs (using anti-Fas mAb) to protect them from tumor counterattack and augment their ability to induce tumor cell apoptosis and stemness inhibition.A significantly increased level of apoptosis and decreased expression of CD 44 (CSCs marker) was observed within the east tumor tissue culture system enriched with Fas molecules and anti-Fas treated PBMCs and the one enriched with Fas molecules only compared to the breast tumor tissues cultured alone (p < 0.001). Accordingly, we can consider the current study as a promising proposed immunotherapeutic strategy for breast cancer.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"163-176"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopy-assisted breast conservation surgery (E-BCS) vs conventional breast conservation surgery (C-BCS) technique for the management of early breast cancer: A systematic review and meta-analysis. 治疗早期乳腺癌的内镜辅助保乳手术(E-BCS)与传统保乳手术(C-BCS)技术:系统综述与荟萃分析。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230023
Arga Patrianagara, Lie Rebecca Yen Hwei

Background: Endoscopy-assisted breast conserving surgery (E-BCS) was developed over 10 years ago as a method for breast cancer treatment with the potential advantage of less noticeable scarring. However, the evidence supporting its superiority over conventional breast conserving surgery (C-BCS) remains unclear.

Objective: This study aims to compare the outcomes of E-BCS and C-BCS for the treatment of early breast cancer.

Methods: A comprehensive search for relevant articles was performed using specific keywords in Medline, Scopus, ClinicalTrials.gov, and Cochrane Library PubMed up to October 17th, 2022. Clinical trials that compared E-BCS with C-BCS in early breast cancer patients were collected.

Results: Our analysis of nine studies revealed that E-BCS was associated with shorter incision length [Mean Difference (MD) -6.50 cm (95% CI -10.75, -2.26), p = 0.003, I2 = 99%] and higher cosmetic score [MD 2.69 (95% CI 1.46, 3.93), p < 0.0001, I2 = 93%] compared with C-BCS. However, E-BCS had a longer operation time [MD 35.95 min (95% CI 19.12, 52.78), p < 0.0001, I2 = 93%] and greater drainage volume [MD 62.91 mL (95% CI 2.55, 123.27), p = 0.04, I2 = 79%]. There was no significant difference in blood loss volume (p = 0.06), drainage duration (p = 0.28), postoperative complications (p = 0.69), or local recurrence (p = 0.59) between the two groups.

Conclusion: Our study suggests that E-BCS offers a shorter incision length and better cosmetic outcome compared with C-BCS in the treatment of early breast cancer. However, E-BCS requires a longer operation time and has greater drainage volume. Further studies are needed to confirm these findings.

背景:内窥镜辅助保乳手术(E-BCS)是十多年前开发的一种乳腺癌治疗方法,其潜在优势是疤痕不明显。然而,支持其优于传统保乳手术(C-BCS)的证据仍不明确:本研究旨在比较 E-BCS 和 C-BCS 治疗早期乳腺癌的效果:截至 2022 年 10 月 17 日,在 Medline、Scopus、ClinicalTrials.gov 和 Cochrane Library PubMed 中使用特定关键词对相关文章进行了全面检索。收集了对早期乳腺癌患者进行 E-BCS 与 C-BCS 比较的临床试验:结果:我们对 9 项研究的分析表明,E-BCS 与较短的切口长度[平均差(MD)-6.50 厘米(95% CI -10.75,-2.26),P = 0.003,I2 = 99%]和较高的美容评分[MD 2.69(95% CI 1.46,3.93),P 结论:我们的研究表明,E-BCS 可为早期乳腺癌患者提供较好的治疗效果:我们的研究表明,在治疗早期乳腺癌时,E-BCS 与 C-BCS 相比,切口长度更短,美容效果更好。然而,E-BCS 需要的手术时间更长,引流量更大。需要进一步的研究来证实这些发现。
{"title":"Endoscopy-assisted breast conservation surgery (E-BCS) vs conventional breast conservation surgery (C-BCS) technique for the management of early breast cancer: A systematic review and meta-analysis.","authors":"Arga Patrianagara, Lie Rebecca Yen Hwei","doi":"10.3233/BD-230023","DOIUrl":"https://doi.org/10.3233/BD-230023","url":null,"abstract":"<p><strong>Background: </strong>Endoscopy-assisted breast conserving surgery (E-BCS) was developed over 10 years ago as a method for breast cancer treatment with the potential advantage of less noticeable scarring. However, the evidence supporting its superiority over conventional breast conserving surgery (C-BCS) remains unclear.</p><p><strong>Objective: </strong>This study aims to compare the outcomes of E-BCS and C-BCS for the treatment of early breast cancer.</p><p><strong>Methods: </strong>A comprehensive search for relevant articles was performed using specific keywords in Medline, Scopus, ClinicalTrials.gov, and Cochrane Library PubMed up to October 17th, 2022. Clinical trials that compared E-BCS with C-BCS in early breast cancer patients were collected.</p><p><strong>Results: </strong>Our analysis of nine studies revealed that E-BCS was associated with shorter incision length [Mean Difference (MD) -6.50 cm (95% CI -10.75, -2.26), p = 0.003, I2 = 99%] and higher cosmetic score [MD 2.69 (95% CI 1.46, 3.93), p < 0.0001, I2 = 93%] compared with C-BCS. However, E-BCS had a longer operation time [MD 35.95 min (95% CI 19.12, 52.78), p < 0.0001, I2 = 93%] and greater drainage volume [MD 62.91 mL (95% CI 2.55, 123.27), p = 0.04, I2 = 79%]. There was no significant difference in blood loss volume (p = 0.06), drainage duration (p = 0.28), postoperative complications (p = 0.69), or local recurrence (p = 0.59) between the two groups.</p><p><strong>Conclusion: </strong>Our study suggests that E-BCS offers a shorter incision length and better cosmetic outcome compared with C-BCS in the treatment of early breast cancer. However, E-BCS requires a longer operation time and has greater drainage volume. Further studies are needed to confirm these findings.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"383-393"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral breast cancer and the influence of body mass index in clinicopathological features and overall survival. 双侧乳腺癌与体重指数对临床病理特征和总生存期的影响。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230014
Carla Luís, Rute Fernandes, João Dias, Deolinda Pereira, João Firmino-Machado, Pilar Baylina, Rúben Fernandes, Raquel Soares

Background: Breast cancer (BC) and obesity are two closely associated pathologies with increasing incidence and mortality rates. Bilateral Breast Cancer (BBC) displays a low incidence rate within BC and obesity represents a major risk factor.

Objective: The aim of this study is to analyzed BBC clinicopathological features distribution and determine the potential influence of obesity in BBC in these same features and overall survival.

Methods: Clinicopathological information was obtained from 42 cases of women with BBC diagnosed in IPO-Porto. To evaluate the frequency distribution of the clinicopathological data, a chi-square goodness of fit test was performed for BBC cases. A chi-square test of independence was applied for BMI stratification. Cox regression was performed for overall survival. Statistical significance was set at p-value < 0.05.

Results: Distribution of BBC clinicopathological features was found to be statistically significant in family history (p-value < 0.001), BBC type (p-value < 0.001), stage (p-value = 0.005), differentiation grade (p-value < 0.001), receptor expression (p-value < 0.001) and histological type (p-value = 0.031). In comparison to the statistical expected results, we observed an increased cases of absence of family history and less cases of metachronous BBC. Histological types between tumours of BBC were mostly concordant. All cases presented concordant receptor expression. Analysis stratified by BMI revealed that obese women were diagnosed later, although without statistical significance. All obese women presented poor differentiation grade (n = 6). Overweight patients display a tendency to a better overall survival with lower tumour stages and lower differentiation grades.

Conclusions: Our results reveal the same receptor expression between contralateral tumours. Also, most tumours share the same histological type. When stratified by BMI, we observed a tendency for overweight women to have improved overall survival.

背景:乳腺癌(BC)和肥胖症是两种密切相关的病症,其发病率和死亡率都在不断上升。双侧乳腺癌(BBC)在 BC 中发病率较低,而肥胖则是其主要风险因素:本研究旨在分析双侧乳腺癌的临床病理特征分布,并确定肥胖对双侧乳腺癌的相同特征和总体生存率的潜在影响:方法:从波尔图国际肿瘤研究所确诊的42例女性BBC患者中获取临床病理学信息。为了评估临床病理数据的频率分布,对 BBC 病例进行了卡方拟合度检验。对体重指数分层进行了卡方独立性检验。对总生存率进行了 Cox 回归。统计学意义以P值<0.05为标准:发现BBC临床病理特征的分布在家族史(P值<0.001)、BBC类型(P值<0.001)、分期(P值=0.005)、分化等级(P值<0.001)、受体表达(P值<0.001)和组织学类型(P值=0.031)方面具有统计学意义。与预期的统计结果相比,我们发现无家族史的病例增多,而近亲BBC的病例减少。BBC肿瘤的组织学类型大多一致。所有病例的受体表达均一致。根据体重指数进行的分层分析表明,肥胖女性确诊时间较晚,但无统计学意义。所有肥胖女性的分化等级都较低(n = 6)。超重患者的总体生存率较高,肿瘤分期和分化等级较低:我们的研究结果显示,对侧肿瘤的受体表达相同。此外,大多数肿瘤具有相同的组织学类型。根据体重指数进行分层后,我们发现超重女性的总生存率有提高的趋势。
{"title":"Bilateral breast cancer and the influence of body mass index in clinicopathological features and overall survival.","authors":"Carla Luís, Rute Fernandes, João Dias, Deolinda Pereira, João Firmino-Machado, Pilar Baylina, Rúben Fernandes, Raquel Soares","doi":"10.3233/BD-230014","DOIUrl":"https://doi.org/10.3233/BD-230014","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) and obesity are two closely associated pathologies with increasing incidence and mortality rates. Bilateral Breast Cancer (BBC) displays a low incidence rate within BC and obesity represents a major risk factor.</p><p><strong>Objective: </strong>The aim of this study is to analyzed BBC clinicopathological features distribution and determine the potential influence of obesity in BBC in these same features and overall survival.</p><p><strong>Methods: </strong>Clinicopathological information was obtained from 42 cases of women with BBC diagnosed in IPO-Porto. To evaluate the frequency distribution of the clinicopathological data, a chi-square goodness of fit test was performed for BBC cases. A chi-square test of independence was applied for BMI stratification. Cox regression was performed for overall survival. Statistical significance was set at p-value < 0.05.</p><p><strong>Results: </strong>Distribution of BBC clinicopathological features was found to be statistically significant in family history (p-value < 0.001), BBC type (p-value < 0.001), stage (p-value = 0.005), differentiation grade (p-value < 0.001), receptor expression (p-value < 0.001) and histological type (p-value = 0.031). In comparison to the statistical expected results, we observed an increased cases of absence of family history and less cases of metachronous BBC. Histological types between tumours of BBC were mostly concordant. All cases presented concordant receptor expression. Analysis stratified by BMI revealed that obese women were diagnosed later, although without statistical significance. All obese women presented poor differentiation grade (n = 6). Overweight patients display a tendency to a better overall survival with lower tumour stages and lower differentiation grades.</p><p><strong>Conclusions: </strong>Our results reveal the same receptor expression between contralateral tumours. Also, most tumours share the same histological type. When stratified by BMI, we observed a tendency for overweight women to have improved overall survival.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"407-414"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast carcinoma presenting with upper limb lymphedema - A rare case. 乳腺癌伴上肢淋巴水肿--一个罕见病例。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230022
Chandan Kumar Jha, Upasna Sinha, Mainak Sinha, Prashant Kumar Singh

Lymphedema (LE) in a breast cancer patient usually results from axillary lymph node dissection, sentinel lymph node biopsy, and/or axillary radiotherapy. Although lymphatic obstruction and consequent LE can occur due to axillary lymph node involvement, such presentation in breast cancer patients has rarely been reported. This report describes the case of a 50-year-old lady with right breast carcinoma who presented with right upper limb lymphedema. Surprisingly, she did not have any bulky axillary lymphadenopathy that could have accounted for lymphedema of the upper limb, but a suspicious breast mass was present on clinical examination. Diagnosis of breast cancer on clinical examination can be challenging in such patients due to breast edema and careful imaging of the breast and axilla with appropriate imaging tools (mammogram, ultrasound, MRI, PET mammography) should be resorted to before excluding malignancy. Lymphoscintigraphy confirmed the findings of lymphedema in the right upper limb and revealed uptake in the epitrochlear lymph nodes of the contralateral limb suggesting that she might had pre-existing widespread "subclinical lymphedema" which presented as "clinical lymphedema" in right upper limb after axillary lymph node/lymphatic involvement by right breast carcinoma.

乳腺癌患者的淋巴水肿(LE)通常是由腋窝淋巴结清扫、前哨淋巴结活检和/或腋窝放疗引起的。虽然腋窝淋巴结受累会导致淋巴管阻塞,进而引起淋巴水肿,但乳腺癌患者出现淋巴水肿的报道并不多见。本报告描述了一例 50 岁女性右乳腺癌患者出现右上肢淋巴水肿的病例。令人惊讶的是,她没有任何可能导致上肢淋巴水肿的肿大腋窝淋巴结病,但临床检查却发现了可疑的乳房肿块。由于乳房水肿,临床检查对这类患者诊断乳腺癌有一定难度,因此在排除恶性肿瘤之前,应使用适当的成像工具(乳房 X 线照相术、超声波、核磁共振成像、乳腺正电子发射计算机断层扫描)对乳房和腋窝进行仔细成像。淋巴管造影证实了右上肢淋巴水肿的发现,并显示对侧肢体的腋窝淋巴结也有摄取,这表明她可能在右乳腺癌导致腋窝淋巴结/淋巴管受累后出现了广泛的 "亚临床淋巴水肿",并表现为右上肢的 "临床淋巴水肿"。
{"title":"Breast carcinoma presenting with upper limb lymphedema - A rare case.","authors":"Chandan Kumar Jha, Upasna Sinha, Mainak Sinha, Prashant Kumar Singh","doi":"10.3233/BD-230022","DOIUrl":"https://doi.org/10.3233/BD-230022","url":null,"abstract":"<p><p>Lymphedema (LE) in a breast cancer patient usually results from axillary lymph node dissection, sentinel lymph node biopsy, and/or axillary radiotherapy. Although lymphatic obstruction and consequent LE can occur due to axillary lymph node involvement, such presentation in breast cancer patients has rarely been reported. This report describes the case of a 50-year-old lady with right breast carcinoma who presented with right upper limb lymphedema. Surprisingly, she did not have any bulky axillary lymphadenopathy that could have accounted for lymphedema of the upper limb, but a suspicious breast mass was present on clinical examination. Diagnosis of breast cancer on clinical examination can be challenging in such patients due to breast edema and careful imaging of the breast and axilla with appropriate imaging tools (mammogram, ultrasound, MRI, PET mammography) should be resorted to before excluding malignancy. Lymphoscintigraphy confirmed the findings of lymphedema in the right upper limb and revealed uptake in the epitrochlear lymph nodes of the contralateral limb suggesting that she might had pre-existing widespread \"subclinical lymphedema\" which presented as \"clinical lymphedema\" in right upper limb after axillary lymph node/lymphatic involvement by right breast carcinoma.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"395-399"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ginger potency on the prevention and treatment of breast cancer. 生姜对预防和治疗乳腺癌的功效。
Pub Date : 2023-01-01 DOI: 10.3233/BD-239003
Andi Nilawati Usman, Budu Manju, Ilhamuddin Ilhamuddin, Mardiana Ahmad, Takko Ab, Andi Ariyandy, Budiaman Budiaman, Athirah Rinandha Eragradini, Intan Idiana Hasan, Sabarisah Hashim, Sartini Sartini, Andi Wardihan Sinrang

Background: Cancer is a type of disease caused by the uncontrolled growth of abnormal cells that can destroy body tissues. The use of traditional medicine naturally uses plants from ginger with the maceration method. The ginger plant is a herbaceous flowering plant with the Zingiberaceacea group.

Methods: This study uses the literature review method by reviewing 50 articles from journals and databases.

Results: A review of several articles, namely ginger has bioactive components such as gingerol. Ginger is used as a treatment in complementary therapies using plants. Ginger is a strategy with many benefits and functions as a nutritional complement to the body. This benefit has shown the effect of anti-inflammatory, antioxidant, and anticancer against nausea and vomiting due to chemotherapy in breast cancer.

Conclusion: Anticancer in ginger is shown by polyphenols associated with anti-metastatic, anti-proliferative, antiangiogenic, anti-inflammatory, cell cycle arrest, apoptosis, and autophagy. Therefore, consuming ginger regularly affects natural herbal therapy with the prevention and treatment of breast cancer and serves as a prevention against the effects of chemotherapy.

背景:癌症是一种由于异常细胞不受控制地生长而导致的疾病,会破坏人体组织。传统医学自然会使用浸渍法处理生姜中的植物。生姜是一种草本开花植物,属于姜科(Zingiberaceacea)植物:本研究采用文献综述法,查阅了期刊和数据库中的 50 篇文章:对多篇文章的综述表明,生姜具有姜醇等生物活性成分。在使用植物的辅助疗法中,生姜被用作一种治疗手段。生姜是一种具有多种益处的策略,具有补充人体营养的功能。这种益处已显示出抗炎、抗氧化和抗癌的效果,可防止乳腺癌化疗引起的恶心和呕吐:生姜中的抗癌物质是与抗转移、抗增殖、抗血管生成、抗炎、细胞周期停滞、细胞凋亡和自噬有关的多酚类物质。因此,经常食用生姜对预防和治疗乳腺癌有天然的草药治疗作用,并可预防化疗的影响。
{"title":"Ginger potency on the prevention and treatment of breast cancer.","authors":"Andi Nilawati Usman, Budu Manju, Ilhamuddin Ilhamuddin, Mardiana Ahmad, Takko Ab, Andi Ariyandy, Budiaman Budiaman, Athirah Rinandha Eragradini, Intan Idiana Hasan, Sabarisah Hashim, Sartini Sartini, Andi Wardihan Sinrang","doi":"10.3233/BD-239003","DOIUrl":"10.3233/BD-239003","url":null,"abstract":"<p><strong>Background: </strong>Cancer is a type of disease caused by the uncontrolled growth of abnormal cells that can destroy body tissues. The use of traditional medicine naturally uses plants from ginger with the maceration method. The ginger plant is a herbaceous flowering plant with the Zingiberaceacea group.</p><p><strong>Methods: </strong>This study uses the literature review method by reviewing 50 articles from journals and databases.</p><p><strong>Results: </strong>A review of several articles, namely ginger has bioactive components such as gingerol. Ginger is used as a treatment in complementary therapies using plants. Ginger is a strategy with many benefits and functions as a nutritional complement to the body. This benefit has shown the effect of anti-inflammatory, antioxidant, and anticancer against nausea and vomiting due to chemotherapy in breast cancer.</p><p><strong>Conclusion: </strong>Anticancer in ginger is shown by polyphenols associated with anti-metastatic, anti-proliferative, antiangiogenic, anti-inflammatory, cell cycle arrest, apoptosis, and autophagy. Therefore, consuming ginger regularly affects natural herbal therapy with the prevention and treatment of breast cancer and serves as a prevention against the effects of chemotherapy.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"207-212"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast metastases from non-primary breast malignancies: What should we know? 非原发性乳腺恶性肿瘤的乳腺转移:我们应该知道什么?
Pub Date : 2023-01-01 DOI: 10.3233/BD-220056
Ángela Santana Valenciano, Luz Divina Juez Sáez, Belén Pérez Mies, Sara Corral Moreno, Sonia Rivas Fidalgo, Jacobo Cabañas Montero

Background: Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies.

Objective: The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution.

Methods: We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included.

Results: Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21-68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13-106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29-136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5-57,5) versus 14 months (IQR 2-24), respectively; p = 0,161].

Conclusions: Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.

背景:乳腺外恶性肿瘤的转移非常罕见,占所有乳腺恶性肿瘤的不到2%。目的:本研究旨在描述我院非原发性乳腺恶性肿瘤乳腺转移的临床病理特征和预后。方法:我们进行了一项回顾性观察性研究,从1985年1月至2020年12月期间的电子医疗记录和病理学数据库中获得了非原发性乳腺恶性肿瘤乳腺转移患者的数据。仅包括经活检诊断的患者。结果:15名被诊断为非原发性乳腺恶性肿瘤乳腺转移的患者包括在内,13名女性(86,67%)和2名男性(13,33%)。初次诊断时的中位年龄为56岁(IQR 21-68)。最常见的原发性恶性肿瘤是黑色素瘤(9/15;60%)。乳腺转移瘤的中位诊断时间为65个月(IQR 13-106)。最常见的诊断方式是CT扫描(10/15;66,67%)。中位随访时间为96个月(IQR 29-136)。8名患者接受了手术(53.3%),是最常见的保乳手术(5/8;62.5%)。随访结束时的死亡率为53.3%(8/15)。在生存率分析中,我们发现接受手术的患者和仅接受全身治疗的患者之间没有差异[41.5个月(IQR 17,5-57,5)和14个月(IQ R 2-24);p=0161]。结论:非原发性乳腺恶性肿瘤的乳腺转移极为罕见,由于这些患者的预后不佳,这是一个诊断和治疗挑战。因此,得出正确的诊断对于避免对这一人群进行不必要的治疗至关重要。
{"title":"Breast metastases from non-primary breast malignancies: What should we know?","authors":"Ángela Santana Valenciano,&nbsp;Luz Divina Juez Sáez,&nbsp;Belén Pérez Mies,&nbsp;Sara Corral Moreno,&nbsp;Sonia Rivas Fidalgo,&nbsp;Jacobo Cabañas Montero","doi":"10.3233/BD-220056","DOIUrl":"10.3233/BD-220056","url":null,"abstract":"<p><strong>Background: </strong>Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies.</p><p><strong>Objective: </strong>The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution.</p><p><strong>Methods: </strong>We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included.</p><p><strong>Results: </strong>Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21-68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13-106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29-136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5-57,5) versus 14 months (IQR 2-24), respectively; p = 0,161].</p><p><strong>Conclusions: </strong>Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"223-228"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymph node microcalcifications after neoadjuvant chemotherapy: A therapeutic response marker. 新辅助化疗后淋巴结微钙化:一个治疗反应标志。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220025
René Aloisio da Costa Vieira, Camila Andrade da Rocha, Pedro Cavalcanti Falcão-Junior, Luiz Carlos Navarro de Oliveira

Lymph node microcalcifications are rare events, and when they are accompanied by neoplasia, they usually seem to be associated with a metastatic condition. We present a case of a patient with breast cancer and lymph node microcalcifications undergoing neoadjuvant chemotherapy (NCT). A change in the calcification pattern towards becoming coarse was observed. Calcification represented a marker of axillary disease, and it was resected after NCT. This is the first report of a patient with lymph node microcalcification undergoing NCT. We observed a change in the calcification format, which facilitated lymph node sentinel identification. Pathological evaluation indicated metastatic disease.

淋巴结微钙化是罕见的事件,当它们伴有瘤变时,它们通常似乎与转移性疾病有关。我们报告一例患有乳腺癌和淋巴结微钙化的患者接受新辅助化疗(NCT)。观察到钙化模式向粗化方向变化。钙化是腋窝疾病的标志,在NCT后予以切除。这是第一个报告的患者与淋巴结微钙化接受NCT。我们观察到钙化形式的变化,这有助于淋巴结前哨的识别。病理检查提示转移性疾病。
{"title":"Lymph node microcalcifications after neoadjuvant chemotherapy: A therapeutic response marker.","authors":"René Aloisio da Costa Vieira,&nbsp;Camila Andrade da Rocha,&nbsp;Pedro Cavalcanti Falcão-Junior,&nbsp;Luiz Carlos Navarro de Oliveira","doi":"10.3233/BD-220025","DOIUrl":"https://doi.org/10.3233/BD-220025","url":null,"abstract":"<p><p>Lymph node microcalcifications are rare events, and when they are accompanied by neoplasia, they usually seem to be associated with a metastatic condition. We present a case of a patient with breast cancer and lymph node microcalcifications undergoing neoadjuvant chemotherapy (NCT). A change in the calcification pattern towards becoming coarse was observed. Calcification represented a marker of axillary disease, and it was resected after NCT. This is the first report of a patient with lymph node microcalcification undergoing NCT. We observed a change in the calcification format, which facilitated lymph node sentinel identification. Pathological evaluation indicated metastatic disease.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9098715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials. 抗体-药物偶联物治疗三阴性和HER-2阳性乳腺癌的疗效和安全性:临床试验的系统回顾和荟萃分析
Pub Date : 2023-01-01 DOI: 10.3233/BD-220052
Fatima Afzal, Wajeeha Aiman, Hafsa Zahoor, Ayfa Riaz Bajwa, Syeda Hafsa Kazmi, Aqsa Anwar, Muhammad Yasir Anwar, Sana Rashid, Hina Zubair, Tooba Kashif, Muhammad Ashar Ali

Breast cancer (BC) is the 2nd most common cause of cancer-related deaths. Antibody-drug conjugates (ADCs) are monoclonal antibodies linked to cytotoxic agents and are directed towards a specific tumor protein. Therefore, they are more potent and can have relatively less toxicity. In this meta-analysis, we assessed the efficacy and safety of ADCs in breast cancer. We searched PubMed, Cochrane, Web of Science, and clinicaltrials.gov for relevant studies and included 7 randomized clinical trials (N = 5,302) and 7 non-randomized clinical trials (N = 658). R programming language software was used to conduct this meta-analysis. In 4 RCTs on HER-2 positive BC (N = 2,825), the pooled HR of PFS and OS was 0.72 (95% CI = 0.61-0.84, I2 = 71%) and 0.73 (95% CI = 0.64-0.84, I2 = 20%), respectively in favor of ADCs versus chemotherapy. In RCT on triple negative BC (N = 468), HR of PFS and OS were 0.55 (95%CI = 0.51-0.61) and 0.59 (95% CI = 0.54-0.66), respectively, in favor of saci-gov versus chemotherapy. In RCT on HER-2 positive residual invasive BC, HR of recurrence/death was 0.61 (95% CI = 0.54-0.69) in favor of ADC versus chemotherapy. In an RCT (N = 524), the HR of PFS and OS were 0.28 (95% CI = 0.22-0.37) and 0.55 (95%CI = 0.36-0.86), respectively, in favor of trastuzumab-deruxtecan (T-der) as compared to trastuzumab-emtansine (T-DM1). Anemia, rash, diarrhea, fatigue, hypertension, thrombocytopenia, and elevated aminotransferases were the common ≥grade 3 adverse events reported in 4%, 1%, 2%, 1%, 2%, 9%, and 3% of the patients, respectively. ADCs were more effective than single and double agent chemotherapy in patients with HER-2 positive or triple negative BC. Among ADCs, T-der was more effective than T-DM1.

乳腺癌(BC)是癌症相关死亡的第二大常见原因。抗体-药物偶联物(adc)是一种与细胞毒性药物连接的单克隆抗体,针对特定的肿瘤蛋白。因此,它们的效力更强,毒性相对更小。在这项荟萃分析中,我们评估了adc治疗乳腺癌的有效性和安全性。我们检索PubMed、Cochrane、Web of Science和clinicaltrials.gov等相关研究,纳入7项随机临床试验(N = 5302)和7项非随机临床试验(N = 658)。采用R编程语言软件进行meta分析。在4个HER-2阳性BC的rct中(N = 2,825), PFS和OS的合并HR分别为0.72 (95% CI = 0.61-0.84, I2 = 71%)和0.73 (95% CI = 0.64-0.84, I2 = 20%),分别支持adc与化疗。在三阴性BC (N = 468)的RCT中,PFS和OS的HR分别为0.55 (95%CI = 0.51-0.61)和0.59 (95%CI = 0.54-0.66),支持saci-gov与化疗。在HER-2阳性残余浸润性BC的RCT中,复发/死亡的HR为0.61 (95% CI = 0.54-0.69),支持ADC与化疗。在一项RCT (N = 524)中,PFS和OS的HR分别为0.28 (95%CI = 0.22-0.37)和0.55 (95%CI = 0.36-0.86),与曲妥珠单抗-emtansine (T-DM1)相比,曲妥珠单抗-德鲁西替康(T-der)更有利。贫血、皮疹、腹泻、疲劳、高血压、血小板减少和转氨酶升高是常见的≥3级不良事件,分别在4%、1%、2%、1%、2%、9%和3%的患者中报道。在HER-2阳性或三阴性BC患者中,adc比单药和双药化疗更有效。adc中,T-der比T-DM1更有效。
{"title":"Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials.","authors":"Fatima Afzal,&nbsp;Wajeeha Aiman,&nbsp;Hafsa Zahoor,&nbsp;Ayfa Riaz Bajwa,&nbsp;Syeda Hafsa Kazmi,&nbsp;Aqsa Anwar,&nbsp;Muhammad Yasir Anwar,&nbsp;Sana Rashid,&nbsp;Hina Zubair,&nbsp;Tooba Kashif,&nbsp;Muhammad Ashar Ali","doi":"10.3233/BD-220052","DOIUrl":"https://doi.org/10.3233/BD-220052","url":null,"abstract":"<p><p>Breast cancer (BC) is the 2nd most common cause of cancer-related deaths. Antibody-drug conjugates (ADCs) are monoclonal antibodies linked to cytotoxic agents and are directed towards a specific tumor protein. Therefore, they are more potent and can have relatively less toxicity. In this meta-analysis, we assessed the efficacy and safety of ADCs in breast cancer. We searched PubMed, Cochrane, Web of Science, and clinicaltrials.gov for relevant studies and included 7 randomized clinical trials (N = 5,302) and 7 non-randomized clinical trials (N = 658). R programming language software was used to conduct this meta-analysis. In 4 RCTs on HER-2 positive BC (N = 2,825), the pooled HR of PFS and OS was 0.72 (95% CI = 0.61-0.84, I2 = 71%) and 0.73 (95% CI = 0.64-0.84, I2 = 20%), respectively in favor of ADCs versus chemotherapy. In RCT on triple negative BC (N = 468), HR of PFS and OS were 0.55 (95%CI = 0.51-0.61) and 0.59 (95% CI = 0.54-0.66), respectively, in favor of saci-gov versus chemotherapy. In RCT on HER-2 positive residual invasive BC, HR of recurrence/death was 0.61 (95% CI = 0.54-0.69) in favor of ADC versus chemotherapy. In an RCT (N = 524), the HR of PFS and OS were 0.28 (95% CI = 0.22-0.37) and 0.55 (95%CI = 0.36-0.86), respectively, in favor of trastuzumab-deruxtecan (T-der) as compared to trastuzumab-emtansine (T-DM1). Anemia, rash, diarrhea, fatigue, hypertension, thrombocytopenia, and elevated aminotransferases were the common ≥grade 3 adverse events reported in 4%, 1%, 2%, 1%, 2%, 9%, and 3% of the patients, respectively. ADCs were more effective than single and double agent chemotherapy in patients with HER-2 positive or triple negative BC. Among ADCs, T-der was more effective than T-DM1.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"121-136"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9747201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Desmoid fibroma simulating malignant breast neoplasm: A case report and literature review. 模拟乳腺恶性肿瘤的筛状纤维瘤:一例报告和文献复习。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230028
Maria Stella Vasconcelos Sales Valente, Fábio Augusto Xerez Mota, Bárbara Bezerra Ricciardi, Bárbara Matos de Carvalho Borges, Enzo Studart de Lucena Feitosa, Pedro Lucena de Aquino, Paulla Vasconcelos Valente

Introduction: Desmoid fibroma (DF) is a disorder characterized by strong clonal proliferation of myofibroblasts and fibroblasts. We describe a case of DF that mimicked a breast tumor, along with a review of the literature on the clinical manifestation, diagnostic process, and course of therapy for this combative disease.

Case report: A 34-year-old female patient with breast lump at the junction of the upper quadrants of the left breast. After the diagnosis of DF, it was decided to perform a sectorectomy of the left breast associated with post-quadrant reconstruction, with immunohistochemistry and findings compatible with DF.

Discussion: Clinically manifests as a solid mass that is often painless and occasionally adherent to the chest wall. A treatment strategy should be idealized for each patient. Thus, there is the possibility of performing radical surgery for resection and/or radiotherapy, and surgery may be followed by radiotherapy.

引言:筛状纤维瘤(DF)是一种以肌成纤维细胞和成纤维细胞的强烈克隆性增殖为特征的疾病。我们描述了一个模仿乳腺肿瘤的DF病例,并回顾了关于这种对抗性疾病的临床表现、诊断过程和治疗过程的文献。病例报告:一名34岁女性患者,左乳房上象限交界处有乳房肿块。在诊断出DF后,决定进行左乳腺切除术,并进行象限后重建,免疫组织化学和结果与DF一致。讨论:临床表现为固体肿块,通常无痛,偶尔粘附在胸壁上。每个病人的治疗策略都应该是理想化的。因此,有可能进行根治性手术进行切除和/或放射治疗,手术后可能进行放射治疗。
{"title":"Desmoid fibroma simulating malignant breast neoplasm: A case report and literature review.","authors":"Maria Stella Vasconcelos Sales Valente,&nbsp;Fábio Augusto Xerez Mota,&nbsp;Bárbara Bezerra Ricciardi,&nbsp;Bárbara Matos de Carvalho Borges,&nbsp;Enzo Studart de Lucena Feitosa,&nbsp;Pedro Lucena de Aquino,&nbsp;Paulla Vasconcelos Valente","doi":"10.3233/BD-230028","DOIUrl":"https://doi.org/10.3233/BD-230028","url":null,"abstract":"<p><strong>Introduction: </strong>Desmoid fibroma (DF) is a disorder characterized by strong clonal proliferation of myofibroblasts and fibroblasts. We describe a case of DF that mimicked a breast tumor, along with a review of the literature on the clinical manifestation, diagnostic process, and course of therapy for this combative disease.</p><p><strong>Case report: </strong>A 34-year-old female patient with breast lump at the junction of the upper quadrants of the left breast. After the diagnosis of DF, it was decided to perform a sectorectomy of the left breast associated with post-quadrant reconstruction, with immunohistochemistry and findings compatible with DF.</p><p><strong>Discussion: </strong>Clinically manifests as a solid mass that is often painless and occasionally adherent to the chest wall. A treatment strategy should be idealized for each patient. Thus, there is the possibility of performing radical surgery for resection and/or radiotherapy, and surgery may be followed by radiotherapy.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"319-323"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Injection mammoplasty: Normal imaging appearances, complications, and implications for mammographic screening. 注射乳房成形术:正常影像表现,并发症,以及对乳房x线摄影筛查的影响。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220059
Winfred Xi Tai Goh, Yien Sien Lee, Sze Yiun Teo

Background: The normal imaging appearances of the common agents used in injection mammoplasty and the challenges of mammography screening will be reviewed.

Methods: The local database from a tertiary hospital was accessed for imaging cases of injection mammoplasty.

Results: Free silicone is seen as multiple high-density opacities on mammograms. Silicone deposits can often be seen within axillary nodes due to lymphatic migration. Sonographically, a snowstorm appearance is seen when the silicone is diffusely distributed. On MRI, free silicone is hypointense on T1-weighted and hyperintense on T2-weighted images, with no contrast enhancement. Mammograms have a limited role in screening due to the high density of silicone. MRI is often required in these patients.Polyacrylamide gel and hyaluronic acid are seen as multiple collections on mammography. Polyacrylamide gel collections are of the same density as cysts, while hyaluronic acid collections are of higher density but less dense than silicone. On ultrasound, both can appear anechoic or show variable internal echoes. MRI demonstrates fluid signal with hypointense T1-weighted and hyperintense T2-weighted signal. Mammographic screening is possible if the injected material is located predominantly in the retro-glandular space without obscuring the breast parenchyma.On mammograms, autologous fat locules appear as lucent masses. Rim calcification can be seen if fat necrosis had developed. On ultrasound, focal fat collections can demonstrate varying levels of internal echogenicity, depending on the stage of fat necrosis. Mammographic screening is usually possible for patients after autologous fat injection as fat is hypodense compared to breast parenchyma. However, the dystrophic calcification associated with fat necrosis may mimic abnormal breast calcification. In such cases, MRI can be utilized as a problem-solving tool.

Conclusion: It is important for the radiologist to recognize the type of injected material on the various imaging modalities and recommend the best modality for screening.

背景:本文将回顾乳腺注射成形术中常用药物的正常影像学表现以及乳腺x线摄影筛查的挑战。方法:对某三级医院的乳腺注射成形术影像资料进行检索。结果:游离硅胶在乳房x光片上表现为多发高密度混浊。由于淋巴迁移,硅酮沉积常可见于腋窝淋巴结内。超声检查,当硅酮弥漫性分布时,可见暴风雪样。在MRI上,游离硅胶在t1加权图像上呈低信号,在t2加权图像上呈高信号,无对比度增强。乳房x光检查在筛查中的作用有限,因为硅酮的密度很高。这些患者通常需要MRI检查。在乳房x光检查中,聚丙烯酰胺凝胶和透明质酸被视为多重集合。聚丙烯酰胺凝胶集合的密度与囊肿相同,而透明质酸集合的密度更高,但密度低于硅胶。在超声波上,两者都可以出现无回声或显示可变的内部回声。MRI显示流体信号伴低t1加权和高t2加权信号。如果注入的物质主要位于腺后间隙而没有遮蔽乳腺实质,则可以进行乳房x线摄影筛查。在乳房x光片上,自体脂肪小囊呈透明团块。如果脂肪坏死,可以看到边缘钙化。在超声上,局灶性脂肪集合可显示不同程度的内部回声,这取决于脂肪坏死的阶段。自体脂肪注射后的患者通常可以进行乳房x光检查,因为与乳腺实质相比,脂肪密度较低。然而,与脂肪坏死相关的营养不良钙化可能与乳房异常钙化相似。在这种情况下,MRI可以作为解决问题的工具。结论:放射科医师在各种成像方式上识别注射物质的类型并推荐最佳筛查方式是很重要的。
{"title":"Injection mammoplasty: Normal imaging appearances, complications, and implications for mammographic screening.","authors":"Winfred Xi Tai Goh,&nbsp;Yien Sien Lee,&nbsp;Sze Yiun Teo","doi":"10.3233/BD-220059","DOIUrl":"https://doi.org/10.3233/BD-220059","url":null,"abstract":"<p><strong>Background: </strong>The normal imaging appearances of the common agents used in injection mammoplasty and the challenges of mammography screening will be reviewed.</p><p><strong>Methods: </strong>The local database from a tertiary hospital was accessed for imaging cases of injection mammoplasty.</p><p><strong>Results: </strong>Free silicone is seen as multiple high-density opacities on mammograms. Silicone deposits can often be seen within axillary nodes due to lymphatic migration. Sonographically, a snowstorm appearance is seen when the silicone is diffusely distributed. On MRI, free silicone is hypointense on T1-weighted and hyperintense on T2-weighted images, with no contrast enhancement. Mammograms have a limited role in screening due to the high density of silicone. MRI is often required in these patients.Polyacrylamide gel and hyaluronic acid are seen as multiple collections on mammography. Polyacrylamide gel collections are of the same density as cysts, while hyaluronic acid collections are of higher density but less dense than silicone. On ultrasound, both can appear anechoic or show variable internal echoes. MRI demonstrates fluid signal with hypointense T1-weighted and hyperintense T2-weighted signal. Mammographic screening is possible if the injected material is located predominantly in the retro-glandular space without obscuring the breast parenchyma.On mammograms, autologous fat locules appear as lucent masses. Rim calcification can be seen if fat necrosis had developed. On ultrasound, focal fat collections can demonstrate varying levels of internal echogenicity, depending on the stage of fat necrosis. Mammographic screening is usually possible for patients after autologous fat injection as fat is hypodense compared to breast parenchyma. However, the dystrophic calcification associated with fat necrosis may mimic abnormal breast calcification. In such cases, MRI can be utilized as a problem-solving tool.</p><p><strong>Conclusion: </strong>It is important for the radiologist to recognize the type of injected material on the various imaging modalities and recommend the best modality for screening.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10847166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1